Chaudhry, Aafia
(Medical Affairs, Novocure Ltd., New York, NY USA)
,
Benson, Laura
(Medical Affairs, Novocure Ltd., New York, NY USA)
,
Varshaver, Michael
(Technical Operations, Novocure Ltd., 195 Commerce Way, Portsmouth, NH USA)
,
Farber, Ori
(Research and Development, Novocure Ltd., Topaz Building, 4th Floor, MATAM Center, PO Box 15022, Sha’ar HaCarmel, Haifa Israel)
,
Weinberg, Uri
(Clinical Development, Novocure Ltd., Park 6, CH-6039 Root D4, Lucerne, Switzerland)
,
Kirson, Eilon
(Research and Development, Novocure Ltd., Topaz Building, 4th Floor, MATAM Center, PO Box 15022, Sha’ar HaCarmel, Haifa Israel)
,
Palti, Yoram
(Research and Development, Novocure Ltd., Topaz Building, 4th Floor, MATAM Center, PO Box 15022, Sha’ar HaCarmel, Haifa Israel)
BackgroundOptune™, previously known as the NovoTTF-100A System™, generates Tumor Treating Fields (TTFields), an effective anti-mitotic therapy for glioblastoma. The system delivers intermediate frequency, alternating electric fields to the supratentorial brain. Patient therapy is personalized by con...
BackgroundOptune™, previously known as the NovoTTF-100A System™, generates Tumor Treating Fields (TTFields), an effective anti-mitotic therapy for glioblastoma. The system delivers intermediate frequency, alternating electric fields to the supratentorial brain. Patient therapy is personalized by configuring transducer array layout placement on the scalp to the tumor site using MRI measurements and the NovoTAL System. Transducer array layout mapping optimizes therapy by maximizing electric field intensity to the tumor site. This study evaluated physician performance in conducting transducer array layout mapping using the NovoTAL System compared with mapping performed by the Novocure in-house clinical team.MethodsFourteen physicians (7 neuro-oncologists, 4 medical oncologists, and 3 neurosurgeons) evaluated five blinded cases of recurrent glioblastoma and performed head size and tumor location measurements using a standard Digital Imaging and Communications in Medicine reader. Concordance with Novocure measurement and intra- and inter-rater reliability were assessed using relevant correlation coefficients. The study criterion for success was a concordance correlation coefficient (CCC) >0.80.ResultsCCC for each physician versus Novocure on 20 MRI measurements was 0.96 (standard deviation, SD ± 0.03, range 0.90–1.00), indicating very high agreement between the two groups. Intra- and inter-rater reliability correlation coefficients were similarly high: 0.83 (SD ±0.15, range 0.54–1.00) and 0.80 (SD ±0.18, range 0.48–1.00), respectively.ConclusionsThis user study demonstrated an excellent level of concordance between prescribing physicians and Novocure in-house clinical teams in performing transducer array layout planning. Intra-rater reliability was very high, indicating reproducible performance. Physicians prescribing TTFields, when trained on the NovoTAL System, can independently perform transducer array layout mapping required for the initiation and maintenance of patients on TTFields therapy.
BackgroundOptune™, previously known as the NovoTTF-100A System™, generates Tumor Treating Fields (TTFields), an effective anti-mitotic therapy for glioblastoma. The system delivers intermediate frequency, alternating electric fields to the supratentorial brain. Patient therapy is personalized by configuring transducer array layout placement on the scalp to the tumor site using MRI measurements and the NovoTAL System. Transducer array layout mapping optimizes therapy by maximizing electric field intensity to the tumor site. This study evaluated physician performance in conducting transducer array layout mapping using the NovoTAL System compared with mapping performed by the Novocure in-house clinical team.MethodsFourteen physicians (7 neuro-oncologists, 4 medical oncologists, and 3 neurosurgeons) evaluated five blinded cases of recurrent glioblastoma and performed head size and tumor location measurements using a standard Digital Imaging and Communications in Medicine reader. Concordance with Novocure measurement and intra- and inter-rater reliability were assessed using relevant correlation coefficients. The study criterion for success was a concordance correlation coefficient (CCC) >0.80.ResultsCCC for each physician versus Novocure on 20 MRI measurements was 0.96 (standard deviation, SD ± 0.03, range 0.90–1.00), indicating very high agreement between the two groups. Intra- and inter-rater reliability correlation coefficients were similarly high: 0.83 (SD ±0.15, range 0.54–1.00) and 0.80 (SD ±0.18, range 0.48–1.00), respectively.ConclusionsThis user study demonstrated an excellent level of concordance between prescribing physicians and Novocure in-house clinical teams in performing transducer array layout planning. Intra-rater reliability was very high, indicating reproducible performance. Physicians prescribing TTFields, when trained on the NovoTAL System, can independently perform transducer array layout mapping required for the initiation and maintenance of patients on TTFields therapy.
1. Stupp R Wong ET Kanner AA Steinberg D Engelhard H Heidecke V NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality Eur J Cancer. 2012 48 2192 2202 10.1016/j.ejca.2012.04.011 22608262
2. Kirson ED Gurvich Z Schneiderman R Dekel E Itzhaki A Wasserman Y Disruption of cancer cell replication by alternating electric fields Cancer Res. 2004 64 3288 3295 10.1158/0008-5472.CAN-04-0083 15126372
3. Kirson ED Dbalý V Tovarys F Vymazal J Soustiel JF Itzhaki A Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors Proc Natl Acad Sci U S A. 2007 104 10152 10157 10.1073/pnas.0702916104 17551011
4. Gutin PH, Wong ET. Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality. Am Soc Clin Oncol Educ Book . 2012:126-131. doi: 10.14694/EdBook_AM.2012.32.126
5. Miranda PC Mekonnen A Salvador R Basser PJ Predicting the electric field distribution in the brain for the treatment of glioblastoma Phys Med Biol. 2014 59 4137 4147 10.1088/0031-9155/59/15/4137 25003941
7. Turner SG Gergel T Wu H Lacroix M Toms SA The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system World J Surg Oncol. 2014 12 162 10.1186/1477-7819-12-162 24884522
8. Artzi M Bokstein F Blumenthal DT Aizenstein O Liberman G Corn BW Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study Eur J Radiol. 2014 83 1250 1256 10.1016/j.ejrad.2014.03.026 24809637
9. de Groot JF Fuller G Kumar AJ Piao Y Eterovic K Ji Y Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice Neuro Oncol. 2010 12 233 242 10.1093/neuonc/nop027 20167811
10. Thompson EM Dosa E Kraemer DF Neuwelt EA Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab J Neurooncol. 2011 103 353 360 10.1007/s11060-010-0397-0 20848300
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.